Dr. Raphael Francisco, MD (he/him) is an Endocrinologist in Tulsa, OK with over 17 years of experience. What is your opinion of Dr. Raphael Francisco, MD? Rate this provider below so other people can make informed decision.
Over 17 Years of Experience
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Raphael Francisco, MD has received over $100,447 which includes payments from the following companies:
$38,187.35 from AstraZeneca Pharmaceuticals LP
$35,531.78 from Janssen Pharmaceuticals, Inc
$6,808.91 from Endo Pharmaceuticals Inc.
$3,958.00 from sanofi-aventis U.S. LLC
$3,773.05 from Corcept Therapeutics
$2,980.08 from Alexion Pharmaceuticals, Inc.
$1,341.81 from Novo Nordisk Inc
$954.13 from LILLY USA, LLC
$944.29 from INSULET CORPORATION
$800.00 from Tandem Diabetes Care, Inc.
$750.55 from GlaxoSmithKline, LLC.
$624.78 from Amgen Inc.
$394.39 from Salix Pharmaceuticals, Ltd
$331.60 from Medtronic MiniMed, Inc.
$300.21 from AbbVie, Inc.
$250.00 from GENZYME CORPORATION
$250.00 from E.R. Squibb & Sons, L.L.C.
$234.69 from Amarin Pharma Inc.
$227.10 from Merck Sharp & Dohme Corporation
$223.97 from Regeneron Pharmaceuticals, Inc.
Payments received by Dr. Raphael Francisco, MD were from the following categories:
$65,100.00 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!